Literature DB >> 35623707

Nanoluciferase-based methods to monitor activation, modulation and trafficking of atypical chemokine receptors.

Rafael Luís1, Giulia D'Uonnolo2, Christie B Palmer2, Max Meyrath3, Tomasz Uchański3, May Wantz3, Bernard Rogister4, Bassam Janji5, Andy Chevigné6, Martyna Szpakowska7.   

Abstract

Chemokines regulate directed cell migration, proliferation and survival and are key components in various physiological and pathological processes. They exert their functions by interacting with seven-transmembrane domain receptors that signal through G proteins (GPCRs). Atypical chemokine receptors (ACKRs) play important roles in the chemokine-receptor network by regulating chemokine bioavailability for the classical receptors through chemokine sequestration, scavenging or transport. Currently, this subfamily of receptors comprises four members: ACKR1, ACKR2, ACKR3 and ACKR4. They differ notably from the classical chemokine receptors by their inability to elicit G protein-mediated signaling, which precludes the use of classical assays relying on the activation of G proteins and related downstream secondary messengers to investigate ACKRs. There is therefore a need for alternative approaches to monitor ACKR activation, modulation and trafficking. This chapter details sensitive and versatile methods based on Nanoluciferase Binary Technology (NanoBiT) and Nanoluciferase Bioluminescence Resonance Energy Transfer (NanoBRET) to monitor ACKR2 and ACKR3 activity through the measurement of β-arrestin and GRK recruitment, and receptor trafficking, including internalization and delivery to early endosomes.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACKR2; ACKR3; ACKR4; Arrestin; CXCR7; Chemokine; GRK3; NanoBRET; NanoBiT; Scavenger

Mesh:

Substances:

Year:  2022        PMID: 35623707     DOI: 10.1016/bs.mcb.2022.03.002

Source DB:  PubMed          Journal:  Methods Cell Biol        ISSN: 0091-679X            Impact factor:   1.441


  1 in total

1.  Nanoluciferase-based cell fusion assay for rapid and high-throughput assessment of SARS-CoV-2-neutralizing antibodies in patient samples.

Authors:  Max Meyrath; Martyna Szpakowska; Jean-Marc Plesseria; Olivia Domingues; Jérémie Langlet; Bernard Weber; Rejko Krüger; Markus Ollert; Andy Chevigné
Journal:  Methods Enzymol       Date:  2022-09-09       Impact factor: 1.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.